Show simple item record

dc.contributor.authorCid-Silva, Purificación
dc.contributor.authorFernández-Bargiela, Noelia
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorBalboa Barreiro, Vanesa
dc.contributor.authorMena, Álvaro
dc.contributor.authorLópez-Calvo, Soledad
dc.contributor.authorVázquez-Rodríguez, Pilar
dc.contributor.authorMartín-Herranz, Isabel
dc.contributor.authorMíguez-Rey, Martín
dc.contributor.authorPoveda, Eva
dc.contributor.authorCastro-Iglesias, Ángeles
dc.date.accessioned2019-03-26T12:56:31Z
dc.date.issued2018-11-02
dc.identifier.citationCid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, et al. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019; 124(4): 479-490es_ES
dc.identifier.issn1742-7835
dc.identifier.urihttp://hdl.handle.net/2183/22365
dc.description.abstract[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for HIV patients. This study evaluated the modifications in the lipid profile of patients who received these treatments in the last three years at our institution. A retrospective observational study in HIV‐infected patients who received EVG/c/FTC/TDF or EVG/c/FTC/TAF from January 2015 to January 2018 at a reference hospital in northwestern Spain was carried out. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed using SPSS software. A total of 384 EVG/c‐based therapies were initiated during the study period, 151 EVG/c/FTC/TDF and 233 EVG/c/FTC/TAF. A significantly negative influence in all the lipid profile parameters in experienced patients and total cholesterol (TC), and LDL‐C in naïve patients were observed after 48 weeks of treatment with EVG/c/FTC/TAF, while these parameters remained stable in the EVG/c/FTC/TDF group. During follow‐up, a greater proportion of patients had lipid levels above the normal range (63.1% TC, 56.2% LDL‐C) and new lipid‐modifying drugs were prescribed (11.9%) in the EVG/c/FTC/TAF group. The number of cardiovascular risk factors (OR 1.66 [95% CI 1.01‐2.72]; P = 0.043) was recognised as an independent predictor of lipid‐lowering prescription for patients treated with both EVG/c/FTC/TDF and EVG/c/FTC/TAF. For patients treated with EVG/c/FTC/TAF, the mean total cholesterol to HDL ratio in the first 48 weeks of the study treatment was associated with a higher likelihood of lipid‐lowering prescription in multivariate analysis (OR 1.6 [95% CI 1.12‐2.52]; P = 0.011). Significant changes in lipid profile have been observed in patients who have received EVG/c/FTC/TAF. It was necessary to prescribe almost twice the number of lipid‐lowering drugs to patients who received EVG/c/FTC/TAF (11.9%) vs EVG/c/FTC/TDF (4.7%).es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.relation.urihttps://doi.org/10.1111/bcpt.13161es_ES
dc.rightsThis is the peer reviewed version of an article which has been publishes in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.es_ES
dc.subjectAdverse eventes_ES
dc.subjectDyslipidemiaes_ES
dc.subjectHIVes_ES
dc.subjectTenofovir alafenamide furamatees_ES
dc.subjectTenofovir disoproxil fumaratees_ES
dc.titleTreatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabinees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2019-11-02es_ES
dc.date.embargoLift2019-11-02
UDC.journalTitleBasic & Clinical Pharmacology & Toxicologyes_ES
UDC.volume124es_ES
UDC.issue4es_ES
UDC.startPage479es_ES
UDC.endPage490es_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record